Shield Therapeutics plc, a specialty pharmaceutical company, in the development and commercialization of hospital-focused pharmaceuticals to treat unmet medical needs. Its lead product is Feraccru, a novel therapy for the treatment of iron deficiency anemia in patients with inflammatory bowel disease. Its advanced pipeline asset is PT20, a novel therapy that has completed its Phase IIb pivotal clinical trial for the treatment of hyperphosphatemia in patients with chronic kidney disease.
Read More…
Industry, Sector and Symbol
Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+44-191-5118500
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales£14.00 million
Profitability
Miscellaneous
Employees15
Next Earnings DateN/A
OptionableOptionable
Shield Therapeutics (LON:STX) Frequently Asked Questions
What is Shield Therapeutics' stock symbol?
Shield Therapeutics trades on the London Stock Exchange (LON) under the ticker symbol "STX."
What price target have analysts set for STX?
3 brokerages have issued 1-year price targets for Shield Therapeutics' shares. Their forecasts range from GBX 116 to GBX 200. On average, they expect Shield Therapeutics' share price to reach GBX 179 in the next year. This suggests that the stock has a possible downside of 3.0%. View Analyst Price Targets for Shield Therapeutics.
What is the consensus analysts' recommendation for Shield Therapeutics?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Shield Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Shield Therapeutics.
Has Shield Therapeutics been receiving favorable news coverage?
Headlines about STX stock have trended neutral on Wednesday, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Shield Therapeutics earned a media sentiment score of 0.4 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Shield Therapeutics.
Who are some of Shield Therapeutics' key competitors?
Some companies that are related to Shield Therapeutics include OrganiGram (OGI), HEXO (HEXO), Next Science (NXS), HLS Therapeutics (HLS), Supreme Cannabis (FIRE), Green Organic Dutchman (TGOD), Benchmark (BMK), ICC Labs (ICC), Flowr (FLWR), Amryt Pharma (AMYT), CannTrust (TRST), Althea Group (AGH), WeedMD (WMD), Probiotec (PBP) and Auscann Group (AC8).
What other stocks do shareholders of Shield Therapeutics own?
Who are Shield Therapeutics' key executives?
Shield Therapeutics' management team includes the folowing people:
- Mr. Carl Sterritt, Co-Founder, CEO & Director (Age 51)
- Mr. Timothy William Watts, Chief Financial Officer (Age 61)
- Fleur Wood, Director of Investor Relations
- Ms. Lucy Bailey, Gen. Counsel & Company Sec.
- Ms. Suzanne Wood, Group HR Director
How do I buy shares of Shield Therapeutics?
Shares of STX and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Shield Therapeutics' stock price today?
One share of STX stock can currently be purchased for approximately GBX 184.50.
How big of a company is Shield Therapeutics?
What is Shield Therapeutics' official website?
How can I contact Shield Therapeutics?
Shield Therapeutics' mailing address is 3rd Fl Baltic Business Quarters, Abbott's Hill, GATESHEAD, NE8 3D, United Kingdom. The company can be reached via phone at +44-191-5118500.
MarketBeat Community Rating for Shield Therapeutics (LON STX)
MarketBeat's community ratings are surveys of what our community members think about Shield Therapeutics and other stocks. Vote "Outperform" if you believe STX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe STX will underperform the S&P 500 over the long term. You may vote once every thirty days.
